Comprehensive identification of signaling pathways for idiopathic pulmonary arterial hypertension

Am J Physiol Cell Physiol. 2020 May 1;318(5):C913-C930. doi: 10.1152/ajpcell.00382.2019. Epub 2020 Mar 11.

Abstract

Whole exome sequencing (WES) was used in the research of familial pulmonary arterial hypertension (FPAH). CAV1 and KCNK3 were found as two novel candidate genes of FPAH. However, few pathogenic genes were identified in idiopathic pulmonary arterial hypertension (IPAH). We conducted WES in 20 unrelated IPAH patients who did not carry the known PAH-pathogenic variants among BMPR2, CAV1, KCNK3, SMAD9, ALK1, and ENG. We found a total of 4,950 variants in 3,534 genes, including 4,444 single-nucleotide polymorphisms and 506 insertions/deletions (InDels). Through the comprehensive and multilevel analysis, we disclosed several novel signaling cascades significantly connected to IPAH, including variants related to cadherin signaling pathway, dilated cardiomyopathy, glucose metabolism, immune response, mucin-type O-glycosylation, phospholipase C (PLC)-activating G protein-coupled receptor (GPCR) signaling pathway, vascular contraction and generation, and voltage-dependent Ca2+ channels. We also conducted validation studies in five mutant genes related to PLC-activating GPCR signaling pathway potentially involved in intracellular calcium regulation through Sanger sequencing for mutation accuracy, qRT-PCR for mRNA stability, immunofluorescence for subcellular localization, Western blotting for protein level, Fura-2 imaging for intracellular calcium, and proliferation analysis for cell function. The validation experiments showed that those variants in CCR5 and C3AR1 significantly increased the rise of intracellular calcium and the variant in CCR5 profoundly enhanced proliferative capacity of human pulmonary artery smooth muscle cells. Thus, our study suggests that multiple genetically affected signaling pathways take effect together to cause the formation of IPAH and the development of right heart failure and may further provide new therapy targets or putative clues for the present treatments such as limited therapeutic effectiveness of Ca2+ channel blockers.

Keywords: Ca2+ signaling; pulmonary hypertension; signaling; whole exome sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Calcium Channel Blockers / adverse effects
  • Calcium Channel Blockers / therapeutic use
  • Calcium Signaling / genetics
  • Caveolin 1 / genetics
  • Cell Proliferation / drug effects
  • Exome Sequencing
  • Familial Primary Pulmonary Hypertension / drug therapy
  • Familial Primary Pulmonary Hypertension / genetics*
  • Familial Primary Pulmonary Hypertension / pathology
  • Female
  • HEK293 Cells
  • Heart Failure / drug therapy
  • Heart Failure / genetics*
  • Heart Failure / pathology
  • Humans
  • Male
  • Middle Aged
  • Myocytes, Smooth Muscle / metabolism
  • Myocytes, Smooth Muscle / pathology
  • Nerve Tissue Proteins / genetics
  • Potassium Channels, Tandem Pore Domain / genetics
  • Pulmonary Artery / metabolism
  • Pulmonary Artery / pathology
  • Receptors, CCR5 / genetics*
  • Receptors, Complement / genetics*
  • Signal Transduction / genetics

Substances

  • CAV1 protein, human
  • CCR5 protein, human
  • Calcium Channel Blockers
  • Caveolin 1
  • Nerve Tissue Proteins
  • Potassium Channels, Tandem Pore Domain
  • Receptors, CCR5
  • Receptors, Complement
  • complement C3a receptor
  • potassium channel subfamily K member 3